Compare $VCEL vs $VRDN | Chartloom

Compare

$VCEL vs $VRDN

Vericel Corp · Viridian Therapeutics Inc

VCEL

Vericel Corp

VRDN

Viridian Therapeutics Inc

Compare $VCEL vs $VRDN

Comparing Vericel Corp and Viridian Therapeutics Inc

VCELVericel Corp

VRDNViridian Therapeutics Inc

VCELVericel Corp

Market cap

$2.05B

P/E (TTM)

86.61x

Forward P/E (NTM)

55.49x

Forward P/S (NTM)

5.56x

Rev growth (TTM)

23.0%

YTD performance

12.6%

52W performance

17.5%

FCF yield

3.0%

VRDNViridian Therapeutics Inc

Market cap

$2.06B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

14.59x

Rev growth (TTM)

23220.3%

YTD performance

-39.2%

52W performance

-12.6%

FCF yield

-16.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

VCEL

VRDN

Detailed metrics comparison

VCEL

Vericel Corp

VRDN

Viridian Therapeutics Inc

Market Cap

VCEL$2.05B

VRDN$2.06B

Enterprise Value

VCEL$1.92B

VRDN$2.25B

Price

VCEL$40.10

VRDN$18.66

P/E Ratio

VCEL86.61x

VRDNN/A

P/S Ratio

VCEL6.69x

VRDN28.97x

EV/Sales

VCEL6.28x

VRDN31.65x

EV/EBITDA

VCEL58.45x

VRDN0.00x

P/B Ratio

VCEL5.56x

VRDN3.58x

P/FCF Ratio

VCEL33.21x

VRDNN/A

EV/FCF

VCEL31.19x

VRDN-6.72x

PEG Ratio

VCEL0.32x

VRDNN/A

Forward P/E (NTM)

VCEL55.49x

VRDNN/A

Forward P/S (NTM)

VCEL5.56x

VRDN14.59x

Revenue (TTM)

VCEL$306M

VRDN$71M

Revenue Growth (YoY)

VCEL23.0%

VRDN23220.3%

Forward Rev Growth

VCEL16.9%

VRDN729.0%

Gross Margin (TTM)

VCEL74.6%

VRDN2.4%

Operating Margin (TTM)

VCEL6.0%

VRDN0.0%

EBITDA Margin (TTM)

VCEL10.2%

VRDN-569.0%

Net Margin (TTM)

VCEL7.9%

VRDN-544.1%

FCF Margin (TTM)

VCEL20.1%

VRDN-471.0%

Net Income (TTM)

VCEL$24M

VRDN$-387M

FCF (TTM)

VCEL$62M

VRDN$-335M

EPS (TTM)

VCEL$0.46

VRDN-$3.59

ROE (TTM)

VCEL6.9%

VRDN-6135.0%

ROA (TTM)

VCEL5.0%

VRDN-4603.0%

ROIC (TTM)

VCEL6.9%

VRDN-5041.0%

Cash

VCEL$125M

VRDN$165M

Debt

VCEL$596K

VRDN$356M

Net Cash/Debt

VCEL$125M

VRDN$-191M

Current Ratio (TTM)

VCEL5.04x

VRDN16.95x

Quick Ratio (TTM)

VCEL4.69x

VRDN16.56x

Debt/Equity (TTM)

VCEL0.00x

VRDN0.54x

Debt/Assets (TTM)

VCEL0.0%

VRDN0.0%

Interest Coverage (TTM)

VCELN/A

VRDNN/A

Net Debt/EBITDA (TTM)

VCEL0.00x

VRDN0.00x

Beta

VCEL1.06

VRDN1.11

52W Performance

VCEL17.5%

VRDN-12.6%

YTD Performance

VCEL12.6%

VRDN-39.2%

% from 52W High

VCEL-18.7%

VRDN-45.6%

% from 52W Low

VCEL38.5%

VRDN41.6%

Asset Turnover (TTM)

VCEL0.63x

VRDN0.08x

FCF Yield (TTM)

VCEL3.0%

VRDN-16.3%

Earnings Yield (TTM)

VCEL1.2%

VRDN-18.8%

Dividend Yield (TTM)

VCELN/A

VRDNN/A

Rule of 40

VCEL43.1

VRDN22,749.3

EV/GP/RG

VCEL0.39

VRDN8.67

Ticker research

View VCEL research View VRDN research

Metric	VCEL Vericel Corp	VRDN Viridian Therapeutics Inc
Market & Valuation
Market Cap	$2.05B	$2.06B
Enterprise Value	$1.92B	$2.25B
Price	$40.10	$18.66
P/E Ratio	86.61x	N/A
P/S Ratio	6.69x	28.97x
EV/Sales	6.28x	31.65x
EV/EBITDA	58.45x	0.00x
P/B Ratio	5.56x	3.58x
P/FCF Ratio	33.21x	N/A
EV/FCF	31.19x	-6.72x
PEG Ratio	0.32x	N/A
Forward P/E (NTM)	55.49x	N/A
Forward P/S (NTM)	5.56x	14.59x
Revenue & Growth
Revenue (TTM)	$306M	$71M
Revenue Growth (YoY)	23.0%	23220.3%
Forward Rev Growth	16.9%	729.0%
Profitability
Gross Margin (TTM)	74.6%	2.4%
Operating Margin (TTM)	6.0%	0.0%
EBITDA Margin (TTM)	10.2%	-569.0%
Net Margin (TTM)	7.9%	-544.1%
FCF Margin (TTM)	20.1%	-471.0%
Net Income (TTM)	$24M	$-387M
FCF (TTM)	$62M	$-335M
EPS (TTM)	$0.46	-$3.59
ROE (TTM)	6.9%	-6135.0%
ROA (TTM)	5.0%	-4603.0%
ROIC (TTM)	6.9%	-5041.0%
Financial Health
Cash	$125M	$165M
Debt	$596K	$356M
Net Cash/Debt	$125M	$-191M
Current Ratio (TTM)	5.04x	16.95x
Quick Ratio (TTM)	4.69x	16.56x
Debt/Equity (TTM)	0.00x	0.54x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.06	1.11
52W Performance	17.5%	-12.6%
YTD Performance	12.6%	-39.2%
% from 52W High	-18.7%	-45.6%
% from 52W Low	38.5%	41.6%
Efficiency & Yields
Asset Turnover (TTM)	0.63x	0.08x
FCF Yield (TTM)	3.0%	-16.3%
Earnings Yield (TTM)	1.2%	-18.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	43.1	22,749.3
EV/GP/RG	0.39	8.67
Ticker research	View VCEL research	View VRDN research

Valuation

P/E Ratio

VCEL

86.61x

P/S Ratio

VCEL

6.69x

VRDN

28.97x

EV/FCF

VRDN

-6.72x

VCEL

31.19x

Growth & revenue

Revenue Growth TTM

VRDN

23220.3%

VCEL

23.0%

Forward Revenue Growth

VRDN

729.0%

VCEL

16.9%

Profitability & performance

Gross Margin

VCEL

74.6%

VRDN

2.4%

ROE

VCEL

6.9%

VRDN

-6135.0%

FCF Yield %

VCEL

3.0%

VRDN

-16.3%

52-Week Performance

VCEL

17.5%

VRDN

-12.6%

Detailed metrics comparison

VCEL

Vericel Corp

VRDN

Viridian Therapeutics Inc

Market Cap

VCEL$2.05B

VRDN$2.06B

Enterprise Value

VCEL$1.92B

VRDN$2.25B

Price

VCEL$40.10

VRDN$18.66

P/E Ratio

VCEL86.61x

VRDNN/A

P/S Ratio

VCEL6.69x

VRDN28.97x

EV/Sales

VCEL6.28x

VRDN31.65x

EV/EBITDA

VCEL58.45x

VRDN0.00x

P/B Ratio

VCEL5.56x

VRDN3.58x

P/FCF Ratio

VCEL33.21x

VRDNN/A

EV/FCF

VCEL31.19x

VRDN-6.72x

PEG Ratio

VCEL0.32x

VRDNN/A

Forward P/E (NTM)

VCEL55.49x

VRDNN/A

Forward P/S (NTM)

VCEL5.56x

VRDN14.59x

Revenue (TTM)

VCEL$306M

VRDN$71M

Revenue Growth (YoY)

VCEL23.0%

VRDN23220.3%

Forward Rev Growth

VCEL16.9%

VRDN729.0%

Gross Margin (TTM)

VCEL74.6%

VRDN2.4%

Operating Margin (TTM)

VCEL6.0%

VRDN0.0%

EBITDA Margin (TTM)

VCEL10.2%

VRDN-569.0%

Net Margin (TTM)

VCEL7.9%

VRDN-544.1%

FCF Margin (TTM)

VCEL20.1%

VRDN-471.0%

Net Income (TTM)

VCEL$24M

VRDN$-387M

FCF (TTM)

VCEL$62M

VRDN$-335M

EPS (TTM)

VCEL$0.46

VRDN-$3.59

ROE (TTM)

VCEL6.9%

VRDN-6135.0%

ROA (TTM)

VCEL5.0%

VRDN-4603.0%

ROIC (TTM)

VCEL6.9%

VRDN-5041.0%

Cash

VCEL$125M

VRDN$165M

Debt

VCEL$596K

VRDN$356M

Net Cash/Debt

VCEL$125M

VRDN$-191M

Current Ratio (TTM)

VCEL5.04x

VRDN16.95x

Quick Ratio (TTM)

VCEL4.69x

VRDN16.56x

Debt/Equity (TTM)

VCEL0.00x

VRDN0.54x

Debt/Assets (TTM)

VCEL0.0%

VRDN0.0%

Interest Coverage (TTM)

VCELN/A

VRDNN/A

Net Debt/EBITDA (TTM)

VCEL0.00x

VRDN0.00x

Beta

VCEL1.06

VRDN1.11

52W Performance

VCEL17.5%

VRDN-12.6%

YTD Performance

VCEL12.6%

VRDN-39.2%

% from 52W High

VCEL-18.7%

VRDN-45.6%

% from 52W Low

VCEL38.5%

VRDN41.6%

Asset Turnover (TTM)

VCEL0.63x

VRDN0.08x

FCF Yield (TTM)

VCEL3.0%

VRDN-16.3%

Earnings Yield (TTM)

VCEL1.2%

VRDN-18.8%

Dividend Yield (TTM)

VCELN/A

VRDNN/A

Rule of 40

VCEL43.1

VRDN22,749.3

EV/GP/RG

VCEL0.39

VRDN8.67

Ticker research

View VCEL research View VRDN research

Metric	VCEL Vericel Corp	VRDN Viridian Therapeutics Inc
Market & Valuation
Market Cap	$2.05B	$2.06B
Enterprise Value	$1.92B	$2.25B
Price	$40.10	$18.66
P/E Ratio	86.61x	N/A
P/S Ratio	6.69x	28.97x
EV/Sales	6.28x	31.65x
EV/EBITDA	58.45x	0.00x
P/B Ratio	5.56x	3.58x
P/FCF Ratio	33.21x	N/A
EV/FCF	31.19x	-6.72x
PEG Ratio	0.32x	N/A
Forward P/E (NTM)	55.49x	N/A
Forward P/S (NTM)	5.56x	14.59x
Revenue & Growth
Revenue (TTM)	$306M	$71M
Revenue Growth (YoY)	23.0%	23220.3%
Forward Rev Growth	16.9%	729.0%
Profitability
Gross Margin (TTM)	74.6%	2.4%
Operating Margin (TTM)	6.0%	0.0%
EBITDA Margin (TTM)	10.2%	-569.0%
Net Margin (TTM)	7.9%	-544.1%
FCF Margin (TTM)	20.1%	-471.0%
Net Income (TTM)	$24M	$-387M
FCF (TTM)	$62M	$-335M
EPS (TTM)	$0.46	-$3.59
ROE (TTM)	6.9%	-6135.0%
ROA (TTM)	5.0%	-4603.0%
ROIC (TTM)	6.9%	-5041.0%
Financial Health
Cash	$125M	$165M
Debt	$596K	$356M
Net Cash/Debt	$125M	$-191M
Current Ratio (TTM)	5.04x	16.95x
Quick Ratio (TTM)	4.69x	16.56x
Debt/Equity (TTM)	0.00x	0.54x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.06	1.11
52W Performance	17.5%	-12.6%
YTD Performance	12.6%	-39.2%
% from 52W High	-18.7%	-45.6%
% from 52W Low	38.5%	41.6%
Efficiency & Yields
Asset Turnover (TTM)	0.63x	0.08x
FCF Yield (TTM)	3.0%	-16.3%
Earnings Yield (TTM)	1.2%	-18.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	43.1	22,749.3
EV/GP/RG	0.39	8.67
Ticker research	View VCEL research	View VRDN research